Free Trial
NASDAQ:MOTS

Motus GI (MOTS) Stock Price, News & Analysis

Motus GI logo
$0.0001 0.00 (0.00%)
(As of 05:37 PM ET)

About Motus GI Stock (NASDAQ:MOTS)

Key Stats

Today's Range
$0.0001
$0.01
50-Day Range
N/A
52-Week Range
$0.00
$1.70
Volume
52,408 shs
Average Volume
543,004 shs
Market Capitalization
$576.90
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

Receive MOTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Motus GI and its competitors with MarketBeat's FREE daily newsletter.

MOTS Stock News Headlines

Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
Motus GI Holdings Inc
See More Headlines

MOTS Stock Analysis - Frequently Asked Questions

Motus GI's stock was trading at $1.2750 on January 1st, 2024. Since then, MOTS shares have decreased by 100.0% and is now trading at $0.0001.
View the best growth stocks for 2024 here
.

Motus GI Holdings, Inc. (NASDAQ:MOTS) released its quarterly earnings data on Friday, November, 12th. The company reported ($30.00) earnings per share for the quarter, meeting the consensus estimate of ($30.00). The firm earned $0.14 million during the quarter, compared to the consensus estimate of $0.12 million. Motus GI had a negative trailing twelve-month return on equity of 1,731.08% and a negative net margin of 3,239.75%.

Shares of Motus GI reverse split on the morning of Thursday, November 2nd 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Motus GI (MOTS) raised $21 million in an initial public offering on Wednesday, February 14th 2018. The company issued 3,500,000 shares at $5.00-$7.00 per share. Piper Jaffray acted as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

Shares of MOTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Motus GI investors own include Inovio Pharmaceuticals (INO), NIO (NIO), Tesla (TSLA), Bionano Genomics (BNGO), Acasti Pharma (ACST) and Pfizer (PFE).

Company Calendar

Last Earnings
11/12/2021
Today
12/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:MOTS
Employees
30
Year Founded
N/A

Profitability

Net Income
$-12,870,000.00
Net Margins
-3,239.75%
Pretax Margin
-3,239.75%

Debt

Sales & Book Value

Annual Sales
$319,000.00
Book Value
$1.74 per share

Miscellaneous

Free Float
5,749,000
Market Cap
$576.90
Optionable
Not Optionable
Beta
1.67
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:MOTS) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners